Search results with tag "Trastuzumab"
DRUG NAME: Trastuzumab emtansine
www.bccancer.bc.caMECHANISM OF ACTION: Trastuzumab emtansine is an antibody -drug conjugate incorporating the monoclonal antibody trastuzumab and emtansine. The emtansine moiety is comprised of two components, DM1, a microtubule inhibitor, and MCC, a thioether linker. Trastuzumab emtansine binds to human epidermal growth factor 2 (HER2) receptors and …
Herceptin® (trastuzumab), Kadcyla®(ado …
www.aetna.comHerceptin ® (trastuzumab), Kadcyla ® Aetna Precertification Notification 503 Sunport Lane, Orlando, FL 32809 (ado-trastuzumab) and Perjeta ® (pertuzumab)
SCIENTIFIC DISCUSSION 1. Introduction
www.ema.europa.euTrastuzumab is formulated as a lyophilised powder and each vial is designed to deliver 150 mg trastuzumab. The finished product also includes 3.36 mg L-Histidine HCl, 2.16 mg L-Histidine, 136.2 mg trehalose, dihydrate, and 0.6 mg polysorbate 20. The sterile solution is filled aseptically into 15 ml Type I borosilicate glass vials with 20 mm
DRUG NAME: Trastuzumab
www.bccancer.bc.caCLASSIFICATION: molecular targeted therapy . Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Trastuzumab is a human monoclonal IgG antibody which selectively targets HER2, a human epidermal growth factor receptor (EGFR).
Breast Pathway Group Subcutaneous Trastuzumab …
www.londoncanceralliance.nhs.ukBreast Pathway Group – Subcutaneous Trastuzumab in Early Stage Breast Cancer Reason for Update: LCA Protocol development Approved by …
Drug Therapy Trastuzumab — Mechanism of …
www.cellbiol.netThe new engl and journal of medicine n engl j med 357;1 www.nejm.org july 5, 2007 39 Drug Therapy Trastuzumab — Mechanism of Action and Use in Clinical Practice Clifford A. Hudis, M.D.
がんのバイオマーカー - Pmda
www.pmda.go.jpTrastuzumab Emtansine ERBB2 (HER2) Indications and Usage, Warnings and Precautions, Adverse Reactions, ... matched therapy: changes from baseline in tumor measurements (waterfall plot). ... An example of an integrative approach to pathway analysis of a drug-sensitive versus drug-resistant population of patients. Nat. Rev. Clin. Oncol.
NEW ZEALAND DATA SHEET Herceptin (trastuzumab)
www.medsafe.govt.nzHerceptin 180501 2 HER2 testing is mandatory prior to initiation of Herceptin therapy (see Dose and Method of Administration, Detection of HER2 Overexpression or Gene Amplification).
DRUG NAME: Trastuzumab - BC Cancer
www.bccancer.bc.carange from mild reactions of chills and/or fever (occurring in 40% of patients with first infusion) to mild-moderate reactions of nausea, vomiting, pain, rigors, headache, cough, dizziness, dyspnea, rash,
BREAST CANCER TREATMENT REGIMENS (Part 1 …
www.just.edu.joBREAST CANCER TREATMENT REGIMENS (Part 2 of 6) REGIMEN DOSING Adjuvant Therapy Without Concomitant Trastuzumab Tamoxifen1,8 Tamoxifen 20–40mg orally daily for no longer than 5 years (doses higher than 20mg should be divided into 2 …
2017 San Antonio Breast Cancer Symposium - …
www.sabcs.org2017 San Antonio Breast Cancer Symposium Publication Number: GS1-02 Title: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with